<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Resist Infect Control</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Resist Infect Control</journal-id><journal-title-group><journal-title>Antimicrobial Resistance and Infection Control</journal-title></journal-title-group><issn pub-type="epub">2047-2994</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4474879</article-id><article-id pub-id-type="publisher-id">2047-2994-4-S1-O6</article-id><article-id pub-id-type="doi">10.1186/2047-2994-4-S1-O6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy of polyhexanide for topical decolonization of methicillin-resistant Staphylococcus aureus (MRSA) carriers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Landelle</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Von Dach</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Haustein</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Agostinho</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Renzi</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Renzoni</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Pittet</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Schrenzel</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Fran&#x000e7;ois</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Harbarth</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Infection Control Program, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland</aff><aff id="I2"><label>2</label>Clinical Microbiology Laboratory, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland</aff><aff id="I3"><label>3</label>Service of Infectious Diseases, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland</aff><aff id="I4"><label>4</label>Genomic Research Laboratory, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2015</year></pub-date><volume>4</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Antimicrobial Resistance and Infection Control: Abstracts from the 3rd International Conference on Prevention and Infection Control (ICPIC 2015)</named-content><named-content content-type="supplement-editor">Didier Pittet, Stephen Harbarth and Andreas Voss</named-content><named-content content-type="supplement-sponsor">Publication of this supplement has been funded by the International Consortium for Prevention and Infection Control (ICPIC). The Supplement Editors declare that they have no competing interests.</named-content></supplement><fpage>O6</fpage><lpage>O6</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Landelle et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Landelle et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.aricjournal.com/content/4/S1/O6"/><conference><conf-date>16-19 June 2015</conf-date><conf-name>3rd International Conference on Prevention and Infection Control (ICPIC 2015)</conf-name><conf-loc>Geneva, Switzerland</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Due to increasing resistance, alternatives to mupirocin and chlorhexidine for decolonization of MRSA carriage need to be evaluated.</p></sec><sec><title>Objectives</title><p>To evaluate the efficacy of polyhexanide (Prontoderm<sup>&#x000ae;</sup>) <italic>vs</italic> placebo in eliminating MRSA carriage at day 28 (D28) after the end of treatment.</p></sec><sec sec-type="methods"><title>Methods</title><p>In a 1,900-bed teaching hospital, MRSA-colonized patients were randomized into a double-blind, placebo-controlled superiority trial. Patients were treated with either polyhexanide (antiseptic and surface-active substances; group I) or placebo (only surface-active substances; group P) applied to the anterior nares and skin for 10 days. The primary outcome was MRSA decolonization at D28 assessed by both intention-to-treat ([ITT] responder analysis) and per-protocol (PP) analysis (microbiological follow-up &#x000b1; 7 days and topical treatment &#x02265; 5 days). Secondary outcomes included MRSA decolonization according to nasal MRSA carriage, safety and emergence of resistance.</p></sec><sec sec-type="results"><title>Results</title><p>Of 2590 patients screened, 146 patients (group I, 71; group P, 75) were randomized between January 2011 and July 2014. Primary outcome was missing for 11 (7.5%) patients. ITT analysis showed that 24/71 (33.8%) patients in group I <italic>vs</italic> 22/75 (29.3%) in group P were MRSA-free at D28 (risk difference, 4.5%; 95% CI, -10.6% to 19.5%; <italic>P</italic>=0.56). PP analysis confirmed the results with 19/53 (35.8%) decolonized polyhexanide-treated patients <italic>vs</italic> 17/56 (30.4%) in the placebo arm (risk difference, 5.5%; 95% CI, -12.2% to 23.0%; <italic>P</italic>=0.54). In the subgroup of MRSA nasal carriers, PP analysis showed that 6/15 (40.0%) patients in group I <italic>vs</italic> 2/11 (18.2%) in group P were decolonized (<italic>P</italic>=0.40). Nine serious adverse events occurred in group I <italic>vs</italic> 12 in group P; none was attributable to study medication. Emergence of polyhexanide resistance was not observed.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>This study suggests that under real-life conditions a single polyhexanide decolonization course is marginally effective in eradicating MRSA carriage.</p></sec><sec><title>Disclosure of interest</title><p>C. Landelle: None declared, E. Von Dach: None declared, T. Haustein: None declared, A. Agostinho: None declared, G. Renzi: None declared, A. Renzoni: None declared, D. Pittet: None declared, J. Schrenzel: None declared, P. Fran&#x000e7;ois: None declared, S. Harbarth Grant/Research support from: a peer-reviewed research grant funded by Pfizer, Consultant for: the advisory boards of Destiny Pharma, bioMerieux, Novartis, and DaVolterra</p></sec></body></article>